Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Ocular Melanoma: early-phase trial registry
3 of 5 indexed Ocular Melanoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 3 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Ocular Melanoma: 5 US clinical trials tracked, 3 recruiting.
Ocular Melanoma is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is H. Lee Moffitt Cancer Center and Research Institute, running 2 of these trials.
Enrollment posture brief
Registry condition ocular-melanoma
OPEN 3 | RECR 60% | LATE 1 | EARLY 3 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Kidney Injury (AKI) (60% recruiting · 5 trials)
Ocular Melanoma lists 3 open slots (60% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Ocular Melanoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Ocular Melanoma is recruiting above its size-band peers.
3 of 5 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Ocular Melanoma research.
H. Lee Moffitt Cancer Center and Research Institute accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Ocular Melanoma trials plan to enrol fewer than 100 people.
Median target enrolment is 42 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.
-
Ocular Melanoma research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Aura Biosciences
NCT06007690
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Iovance Biotherapeutics
NCT06940739
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT05524935
Eye Plaque Brachytherapy for Ocular Melanoma
Duke University
NCT06432660
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT05628883
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Ocular Melanoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Ocular Melanoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Ocular Melanoma page
5 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Ocular Melanoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- H. Lee Moffitt Cancer Center and Research Institute sponsors the most Ocular Melanoma trials on record, review their full trial history before evaluating a specific study. See H. Lee Moffitt Cancer Center and Research Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ocular Melanoma condition card totals 5 registered trials; most-linked intervention TBio-4101; top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.